KURA Valuation

Kura Oncology Inc

Add to Watchlist

Advanced Chart

8.440

+0.35(4.326%)1D

Overview
Forecast
Valuation
Earnings

KURA Relative Valuation

KURA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KURA is overvalued; if below, it's undervalued.

Historical Valuation

Kura Oncology Inc (KURA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.06 is considered Undervalued compared with the five-year average of -7.45. The fair price of Kura Oncology Inc (KURA) is between 117.60 to 130.38 according to relative valuation methord. Compared to the current price of 8.09 USD , Kura Oncology Inc is Undervalued By 93.12%.

Relative Value

Fair Zone

117.60-130.38

Current Price：8.09

93.12%

Undervalued

-3.15

Trailing

Forward

-0.33

EV/EBITDA

Kura Oncology Inc. (KURA) has a current EV/EBITDA of -0.33. The 5-year average EV/EBITDA is -4.08. The thresholds are as follows: Strongly Undervalued below -12.37, Undervalued between -12.37 and -8.23, Fairly Valued between 0.06 and -8.23, Overvalued between 0.06 and 4.20, and Strongly Overvalued above 4.20. The current Forward EV/EBITDA of -0.33 falls within the Historic Trend Line -Fairly Valued range.

-0.51

EV/EBIT

Kura Oncology Inc. (KURA) has a current EV/EBIT of -0.51. The 5-year average EV/EBIT is -4.13. The thresholds are as follows: Strongly Undervalued below -11.98, Undervalued between -11.98 and -8.05, Fairly Valued between -0.20 and -8.05, Overvalued between -0.20 and 3.72, and Strongly Overvalued above 3.72. The current Forward EV/EBIT of -0.51 falls within the Historic Trend Line -Fairly Valued range.

3.94

Kura Oncology Inc. (KURA) has a current PS of 3.94. The 5-year average PS is 8.29. The thresholds are as follows: Strongly Undervalued below -189.18, Undervalued between -189.18 and -90.45, Fairly Valued between 107.02 and -90.45, Overvalued between 107.02 and 205.76, and Strongly Overvalued above 205.76. The current Forward PS of 3.94 falls within the Historic Trend Line -Fairly Valued range.

4.29

P/OCF

Kura Oncology Inc. (KURA) has a current P/OCF of 4.29. The 5-year average P/OCF is -8.91. The thresholds are as follows: Strongly Undervalued below -23.03, Undervalued between -23.03 and -15.97, Fairly Valued between -1.85 and -15.97, Overvalued between -1.85 and 5.21, and Strongly Overvalued above 5.21. The current Forward P/OCF of 4.29 falls within the Overvalued range.

-59.78

P/FCF

Kura Oncology Inc. (KURA) has a current P/FCF of -59.78. The 5-year average P/FCF is -9.87. The thresholds are as follows: Strongly Undervalued below -36.40, Undervalued between -36.40 and -23.14, Fairly Valued between 3.40 and -23.14, Overvalued between 3.40 and 16.67, and Strongly Overvalued above 16.67. The current Forward P/FCF of -59.78 falls within the Strongly Undervalued range.

Kura Oncology Inc (KURA) has a current Price-to-Book (P/B) ratio of 2.30. Compared to its 3-year average P/B ratio of 2.25 , the current P/B ratio is approximately 2.20% higher. Relative to its 5-year average P/B ratio of 2.53, the current P/B ratio is about -9.31% higher. Kura Oncology Inc (KURA) has a Forward Free Cash Flow (FCF) yield of approximately 16.95%. Compared to its 3-year average FCF yield of -6.66%, the current FCF yield is approximately -354.53% lower. Relative to its 5-year average FCF yield of -7.06% , the current FCF yield is about -340.29% lower.

2.40

P/B

Median3y

2.25

Median5y

2.53

17.50

FCF Yield

Median3y

-6.66

Median5y

-7.06

Performance Decomposition

Market capitalization of KURA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of KURA in the past 1 year is driven by Unknown.